Parenteral iron use in the management of anemia in end-stage renal disease patients

American Journal of Kidney Diseases

Volumn 35, Issue 1, 2000, Pages 1-12

  Bailie, George R ^a,b,c,d   Johnson, Curtis A ^a,b,c,d   Mason, Nancy A ^a,b,c,d  

^a MAHLE Engine Components USA Inc   (United States)

^b ALBANY COLLEGE OF PHARMACY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anemia; Dialysis; End stage renal disease (ESRD); Erythropoietin (EPO); Hemodialysis (HD); Iron dextran; Iron gluconate; Iron saccharate; Iron sucrose; Peritoneal dialysis (PD)

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; ENALAPRIL; FERRIC HYDROXIDE SUCROSE; FERRIC OXIDE; FERROUS GLUCONATE; IRON; IRON DEXTRAN; IRON LECITHIN COMPLEX; IRON SACCHARATE; METHYLPREDNISOLONE; NANDROLONE DECANOATE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VENOFERRUM;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; HEMODIALYSIS; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; NONHUMAN; PERITONEAL DIALYSIS;

EID: 0033981609     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(00)70294-0     Document Type: Article

References (53)

1. National Kidney Foundation DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure Am J Kidney Dis 30 suppl 3 1997 S192 S240
2. K Rosenlof SM Kivivuori C Gronhagen-Riska AM Teppo MA Slimes Iron availability is transiently improved by iv iron medication in patients on chronic hemodialysis Clin Nephrol 43 1995 249 255
3. AR Nissenson RM Lindsay S Swan P Seligman J Strobos Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial Am J Kidney Dis 33 1999 471 482
4. G Sunder-Plassmann WH Horl Erythropoietin and iron Clin Nephrol 47 1997 141 157
5. EW Young WE Bloembergen JD Woods G Emmert FK Port RA Wolfe CA Jones PJ Held Iron use among erythropoietin-treated U.S. hemodialysis patients J Am Soc Nephrol 8 1997 1469A (abstr)
6. US Renal Data System Extracts From USRDS 1998 Annual Data Report Am J Kidney Dis 32 suppl 1 1998 S81 S88
7. M Auerbach J Winchester A Wahab K Richards M McGinley F Hall J Anderson G Briefel A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients Am J Kidney Dis 31 1998 81 86
8. D Saltissi D Sauvage J Westhuyzen Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin Clin Nephrol 49 1998 45 48
9. DJ Roe AM Harford PG Zager TB Wiltbank L Kirlin AM Della Valle DB Van Wyck Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents Am J Kidney Dis 28 1996 855 860
10. IC Macdougall B Tucker J Thompson CRV Tomson LRI Baker AEG Raine A randomized controlled study of iron supplementation in patients treated with erythropoietin Kidney Int 50 1996 1694 1699
11. N Ahsan Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in PD patients: A single center comparative study J Am Soc Nephrol 9 1998 664 668
12. S Fishbane N Ahsan Intravenous infusion of total dose iron in peritoneal dialysis patients: A critical appraisal Am J Kidney Dis 32 1998 1086 1090
13. H Suh NK Wadhwa Iron dextran treatment in peritoneal dialysis patients on erythropoietin Adv Perit Dial 8 1992 444 446
14. B Bastani S Gulley Intraperitoneal iron dextran as a potential route of iron therapy in CAPD patients Perit Dial Int 16 1996 646 648
15. S-E Park ZJ Twardowski HL Moore R Khanna KD Nolph Chronic administration of iron dextran into the peritoneal cavity of rats Perit Dial Int 17 1997 179 185
16. JA Sloand MA Shelley AL Erenstone MJ Schiff TE Talley MP Dhakal Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies Perit Dial Int 18 1998 522 527
17. A Shimada Adverse reactions to total dose infusion of iron dextran Clin Pharm 1 1982 248 249
18. R Lange M Diamant JJM Marx Parenteral administration of iron: Possibilities and risks Pharmaceutisch Weekblad 132 1997 103 111
19. G Sunder-Plassmann WH Horl Safety aspects of parenteral iron in patients with end-stage renal disease Drug Safety 17 1997 241 250
20. GR Bailie DL Frankenfield BF Prowant W McClellan MV Rocco Erythropoietin use and hematocrit control in peritoneal dialysis patients: Report from the 1997 HCFA End-Stage Renal Disease Core Indicators Project Am J Kidney Dis 33 1999 1187 1189
21. M Auerbach D Witt W Toler M Fierstein RG Lerner H Ballard Clinical use of the total dose iv infusion of iron dextran J Lab Clin Med 111 1988 566 570
22. S Fishbane V-D Ungureanu JK Maesaka CJ Kaupke V Lim J Wish The safety of intravenous iron dextran in hemodialysis patients Am J Kidney Dis 28 1996 529 534
23. AW Richter HI Hedin Dextran hypersensitivity Immunol Today 3 1982 132 138
24. MS Monaghan G Glasco G St John RW Bradsher KM Olsen Safe administration of iron dextran to a patient who reacted to the test dose South Med J 87 1994 1010 1012
25. LC Altman PE Petersen Successful prevention of an anaphylactoid reaction to iron dextran Ann Intern Med 109 1988 346 347 (letter)
26. M Auerbach M Chaudry H Goldman H Ballard Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial J Lab Clin Med 131 1998 257 260
27. A Collins J Ebben J Ma Frequent IV iron dosing is associated with higher infectious deaths J Am Soc Nephrol 8 1997 190A (abstr)
28. A Besarab WK Bolton JK Browne JC Egrie AR Nissenson DM Okamoto SJ Schwab DA Goodkin The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving HD and epoetin N Engl J Med 339 1998 584 590
29. B Hoen M Kessler D Hestin D Mayeax Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey Nephrol Dial Transplant 10 1995 377 381
30. S Fishbane Iron treatment: Impact of safety issues Am J Kidney Dis 32 suppl 4 1998 S152 S156
31. WL St. Peter LJ Lambrecht M Macres Randomized cross-over study of adverse reactions and cost implications of iv push compared with infusion of iron dextran in hemodialysis patients Am J Kidney Dis 28 1996 523 528
32. K Krzysko W Bokowski LM Wichlinski Pharmacokinetics of serum iron in humans Zbl Pharm 123 1984 598 599
33. DS Silverberg A Iaina G Peer E Kaplan BA Levi N Frank S Steinbruch M Blum Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis Am J Kidney Dis 27 1996 234 238
34. DS Silverberg M Blum G Peer E Kaplan A Iaina Intravenous ferric saccharate as an iron supplement in dialysis patients Nephron 72 1996 413 417
35. A Vychytil M Haag-Weber Iron status and iron supplementation in peritoneal dialysis patients Kidney Int 55 suppl 69 1999 S71 S78
36. D-C Tarng T-P Huang TW Chen Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy Am J Nephrol 17 1997 158 164
37. P Geisser M Baer E Schaub Structure/histotoxicity relationship of parenteral iron preparations Arzneim-Forsch/Drug Res 42 1992 1439 1452
38. R Hoigne C Breymann UP Kunzi F Brunner Parenteral iron therapy: Problems and possible solutions Schweiz Med Wochenschr 128 1998 528 535
39. O Nyvad H Danielsen S Madsen Intravenous iron-sucrose complex to reduce epoietin demand in dialysis patients Lancet 344 1994 1305 1306
40. J Pascual JL Teruel F Liano A Sureda J Ortuna Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis Clin Nephrol 35 1991 84
41. J Pascual JL Teruel F Liano A Sureda J Ortuna Serious adverse reactions after intravenous ferric gluconate Nephrol Dial Transplant 7 1992 271 272
42. J Pascual JL Teruel F Liano A Sureda J Ortuno Intravenous Fe-gluconate-Na for iron-deficient patients on hemodialysis Nephron 60 1992 121
43. JE Taylor N Peat C Porter AG Morgan Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients Nephrol Dial Transplant 11 1996 1079 1083
44. JF Navarro JL Teruel F Liano R Marcen J Ortuno Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body stores in hemodialysis patients Am J Nephrol 16 1996 268 272
45. JF Navarro JL Teruel Sodium ferric gluconate and iron requirements in hemodialysis patients Clin Nephrol 48 1997 202
46. V Allegra G Mengozzi A Vasile Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments Nephron 57 1991 175 182
47. F Rolla D Bucca L Bussino Systemic reactions to iv iron therapy in patients receiving angiotensin converting enzyme inhibitor J Allergy Clin Immunol 93 1994 1074 1075
48. AL Zanen HJ Adriaansen EFH van Bommel R Posthuma GMTh deJong ‘Oversaturation’ of transferrin after ferric gluconate (Ferrlecit®) in haemodialysis patients Nephrol Dial Transplant 11 1996 820 824
49. G Faich J Strobos Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans Am J Kidney Dis 33 1999 464 470
50. AR Nissenson S Swan LL Lambrecht P Anderson S Schweitzer Ferric gluconate (Ferrlecit®) is safe in hemodialysis patients who react to iron dextran J Am Soc Nephrol 7 1996 1460A (abstr)
51. S Fishbane GL Frei J Maesaka Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation Am J Kidney Dis 26 1995 41 46
52. L Park T Uhtoff M Tierney S Nadler Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients Am J Kidney Dis 31 1998 835 840
53. PA Seligman RB Schleicher Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran Clin Chem 45 1999 898 901